Endoscopic changes in the stomach and duodenal mucosa caused by minidose acetylsalicylic acid therapy and their prevention;Endoskopické změny sliznice žaludku a dvanáctníku při léčbě minidávkou acetylsalicylové kyseliny a jejich prevence

Vnitrni Lekarstvi

Volumn 53, Issue 10, 2007, Pages 1053-1056

  Novotný, Ivo ^a   Dite P ^a   Kunovska M ^a   Munzova H ^a  

^a Pracovi t Bohunice   (Czech Republic)

Author keywords

Acetylsalicylic acid; Mucosa erosion; Omeprazole

Indexed keywords

ACETYLSALICYLIC ACID; OMEPRAZOLE; PROTON PUMP INHIBITOR; ANTIULCER AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDICATION; DUODENUM DISEASE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; PROPHYLAXIS; RISK FACTOR; STOMACH EROSION; STOMACH HEMORRHAGE; TREATMENT DURATION; ADULT; AGED; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DUODENUM; FEMALE; INTESTINE MUCOSA; MALE; MIDDLE AGED; PATHOLOGY; PEPTIC ULCER; STOMACH MUCOSA;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ASPIRIN; DUODENUM; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRIC MUCOSA; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMP INHIBITORS;

EID: 36049038302     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Aspirin Myocarcial Infarction Study Research Group: A randomized, controlled trial of aspirin in patients recovered from myocardial infarction. JAMA 1980; 243: 661-669.
2. Harrington RA, Becker RC, Ezekowitz M et al. Anthithrombotic Therapy for Coronary Heart Disease - The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 513S-548S.
3. Lanas A, Bajador E, Serrano P et al. Nitrovasodilators, low dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 348: 834-839.
4. Kelly JP, Kaufman DW, Jurgelon JM et al. Risk of aspirin associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413-1416.
5. Cryer B, Luk G, Feldman M. Effects of very low doses of aspirin on gastric, duodenal and rectal prostaglandins and mucosal injury. Gastroenterology 1995; 108: A77.
6. Cryer B. Nonsteroidal anti-inflammatory drug injury. In: Feldman M (ed). Sleisenger& Fordtran's, Gastrointestinal and Liver Disease. 7th ed. Philadelphia: WB Saunders 2002: 408-430.
7. Feldman M, Shewmake K, Cryer B. Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1113-G1120.
8. Niv Y, Battler A, Abuksis G et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci 2005; 50: 78-80.
9. Singh G, Triadafilopoulos G. Epidemiology of NSAID-induced GI complications. J Rheumatol Suppl 1999; 56: 18-24.
10. Lanas A, Garcia-Rodriguez LA, Arroyo MT et al. NSAIDs, aspirin, PPIs and the risks of upper GI bleeding in common clinical practice. Gastroenterology 2005; 128(Suppl2): A95.
11. Rodrigues LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal antiinflammatory drugs. Lancet 1994; 343: 769-772.
12. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal antiinflammatory drugs. Ann Intern Med 1991; 115: 787-796.
13. Derry S, Kong Loke Y. Risk of gastrointestinal haemorrhage with long term use of aspirin: metaanalysis. BMJ 2000; 321: 1183-1187.
14. Kelly JP, Kaufman DW, Jurgelon JM et al. Risk as aspirin-associated major upper-gastrointestinal bleeding eith anteric-coated or buffered product. Lancet 1996; 348: 1413-1416.
15. Stack WA, Atherton JC, Hawkey GM et al. Interaction between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002; 16: 497-506.
16. Lanas A, Fuentes J, Benizo R et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16: 779-786.
17. Chan FKL, Sung JJY, Chung SSC et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-979.
18. Venerito M, Treiber G, Wex T et al. Effects of low-dose aspirin on gastroic mucosal prostaglandin - E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 1225-1233.
19. Lahij RFJ, Van Rossum LGM, Jansen JBMJ et al. Proton-pump inhibitor therapy for acetysalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther 2003; 18: 109-115.
20. Chuen Lai K, Lam Kum S, Man Chu K et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-2038.
21. Yeomans ND, Lanas A, Talley NJ et al. Prevention of low dose aspirin-associated gastroduodenal ulcers and upper gastrointestinal symptoms in patients receivin esomeprazole 20 mg per day. Gastroenterology 2006; 130(Suppl 4): A81 (abstrakt 561).